

## ANSWERING REVIEWERS



October 22, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 5409-Review.doc).

**Title:** Immunotherapy for colorectal cancer

**Author:** Shigeo Koido, Toshifumi Ohkusa, Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Zensho Ito, Hiroko Kobayashi, Keisuke Saito, Shintaro Tsukinaga, Shunichi Odahara, Mikio Kajihara, Kan Uchiyama, Seiji Arihiro, Hiroo Imazu, Hiroshi Arakawa, Shin Kan, Hideo Komita, Yuko Kamata, Masaki Ito, Jianlin Gong, Hisao Tajiri

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 5409**

The manuscript has been improved according to the suggestions of reviewers:

We find the comments of the reviewers to be useful and agree that the suggested changes will substantially improve our manuscript.

**Reviewer #1 Minor revision**

A good review. I think informative Table that shows mechanism and clinical/experimental outcome of each immunotherapy (peptide, DC, whole tumor cell, viral vector, and their combination) is necessary and important.

(Response)

As suggested, I added Table 1.

**Reviewer #2 Minor revision**

Overall the review article is well presented with good coverage of sections of the relevant literature and is written in a clear style for the non-specialist.

Suggestions for revision and improvement are:

1. The description on regulatory T cells is superficial and does not account for the all of these cell types. No mention is made of gamma-delta T cells or NK cells (See recent review in Cell Mol. Immunol.) which have been used as an experimental cancer therapy in humans. There is also no mention of adoptive T cell transfer therapy for cancer.

(Response) As suggested I mentioned more details about immune suppressive cells. Moreover, I added Figure 1.

I mentioned gamma-delta T cells, NK cells, and adoptive T cell transfer therapy for cancer.

2. Antibody-based cancer immunotherapy is not noted in any detail and cytokine therapy is mentioned only in passing as an adjuvant therapy.

(Response) As suggested, I mentioned antibody-based cancer immunotherapy and cytokine therapy.

3. The manuscript is very text dense and would benefit from the inclusion of

additional tables and/or figures.

(Response) As suggested, I added 2 Figures and 1Table.

4.The future developments of immunotherapy needs to better addressed providing a clearer idea of what new types of therapy are in development and the direction being taken for the discovery of new therapies.

(Response) As suggested, I mentioned more details about Future perspective.

Our manuscript was edited for *World Journal of Gastroenterology* type by American Journal Experts: <http://www.journalexperts.com>.

We are enclosing the entire revised manuscript, Figures and Table. The underline in the manuscript indicates the changes.

We do appreciate the time and effort that the reviewers have put into helping us with this manuscript and we hope that it is now suitable for publication in *World Journal of Gastroenterology*.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in black ink that reads "Shigeo Koido". The script is cursive and fluid, with the first letters of "Shigeo" and "Koido" being capitalized and prominent.

Shigeo Koido, M.D.

Division of Gastroenterology and Hepatology,

Department of Internal Medicine,

The Jikei University School of Medicine, Tokyo, Japan

163-1 Kashiwa-shita Kashiwa, Chiba 277-8564 Japan.

**Fax:** +81-4-7163-3488.

Shigeo\_koido@jikei.ac.jp